Journal of Neurorestoratology
Volume 8

Number 2

Article 2

2020

Clinical neurorestorative cell therapies: Developmental process,
current state and future prospective
Hongyun Huang
Institute of Neurorestoratology, The Third Medical Centre, Chinese PLA General Hospital, Beijing 100853,
China Beijing Hongtianji Neuroscience Academy, Beijing 100144, China

Lin Chen
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine
Beijing 100007, China

Gengsheng Mao
Institute of Neurorestoratology, The Third Medical Centre, Chinese PLA General Hospital, Beijing 100853,
China

Hari Shanker Sharma
Int. Exp. CNS Injury & Repair, Neurobiology (MRC) & Neuroanatomy (UU), Uppsala University, University
Hospital, Anesthesiology & Intensive Care Medicine, Dept. Surgical Sciences, Uppsala, Sweden

Follow this and additional works at: https://tsinghuauniversitypress.researchcommons.org/journal-ofneurorestoratology
Part of the Biomedical Engineering and Bioengineering Commons, Nervous System Diseases
Commons, Neurology Commons, Neurosciences Commons, and the Neurosurgery Commons

Recommended Citation
Hongyun Huang, Lin Chen, Gengsheng Mao et al. Clinical neurorestorative cell therapies: Developmental
process, current state and future prospective. Journal of Neurorestoratology 2020, 8(2): 61-82.

This Research Article is brought to you for free and open access by Tsinghua University Press: Journals Publishing.
It has been accepted for inclusion in Journal of Neurorestoratology by an authorized editor of Tsinghua University
Press: Journals Publishing.

Journal of Neurorestoratology
DOI 10.26599/JNR.2020.9040009

2020, 8(2): 61–82
ISSN 2324-2426

REVIEW ARTICLE

Clinical neurorestorative cell therapies: Developmental process, current
state and future prospective
Hongyun Huang1,2(), Lin Chen3, Gengsheng Mao1, Hari Shanker Sharma4
1

Institute of Neurorestoratology, The Third Medical Centre, Chinese PLA General Hospital, Beijing 100853, China

2

Beijing Hongtianji Neuroscience Academy, Beijing 100144, China

3

Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine Beijing 100007, China

Int. Exp. CNS Injury & Repair, Neurobiology (MRC) & Neuroanatomy (UU), Uppsala University, University Hospital, Anesthesiology
& Intensive Care Medicine, Dept. Surgical Sciences, Uppsala, Sweden
4

ARTICLE INFO

ABSTRACT

Received: 10 May 2020
Revised: 25 May 2020
Accepted: 28 May 2020

Clinical cell therapies (CTs) for neurological diseases and cellular
damage have been explored for more than 2 decades. According to the
United States Food and Drug Administration, there are 2 types of cell
categories for therapy, namely stem cell‐derived CT products and
mature/functionally differentiated cell‐derived CT products. However,
regardless of the type of CT used, the majority of reports of clinical CTs
from either small sample sizes based on single‐center phase 1 or 2
unblinded trials or retrospective clinical studies showed effects on
neurological improvement and the ability to either partially or
temporarily thwart the deteriorating cellular processes of the
neurodegenerative diseases. There have been only a few prospective,
multicenter, randomized, double‐ blind placebo‐control clinical trials of
CTs so far in this developing novel area that have shown negative
results, and more clinical trials are needed. This will expand our
knowledge in exploring the type of cells that yield promising results and
restore damaged neurological structure and functions of the central
nervous system based on higher level evidence‐based medical data. In
this review, we briefly introduce the developmental process, current
state, and future prospective for clinical neurorestorative CT.
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1

Introduction

Clinical cell therapies (CTs) have been explored
for neurological diseases for more than 20 years.
Preliminary results showed that of most CTs
restore neurological structure and functions to
some degree for a period of time. These results

were promising and evoked hope in patients,
health care providers, and the clinical scientific
community. However, compared with the initial
clinical results, follow‐up studies of CTs
exhibited more or less similar results without
any breakthroughs. According to the United
States Food and Drug Administration (USFDA)
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for cell categories (Guidance for Industry: Pre‐
clinical Assessment of Investigational Cellular and
Gene Therapy Products; http://www.fda.ov Bio‐
logicsBloodVaccines/GuidanceComplianceRegula
toryInformation/Guidances/default.htm), CTs are
divided into either stem cell‐derived CT
products and mature/functionally differentiated
cell‐derived CT products. In this review, we
briefly emphasize the main clinical neurorestorative
CTs with developmental processes, current state
of the art, and future prospectives.

2

Developmental process and current state
of mature/functional cells

Mature/functional cells used in the nervous
system include neuronal cells, olfactory ensheathing
cells (OECs), mononuclear cells (MNCs), mesen‐
chymal stromal cells (MSCs), Schwann cells
(SCs), fetal brain or spinal cord cells, and similar
cell types.
2.1

Neuronal cells

In 2000, a study was reported indicating that
transplanting neurons originating from teratocar‐
cinoma showed functional improvements in
patients with chronic stroke [1]. However, in a later
randomized, observer‐blinded trial, these cells
did not show any effect [2]. Interestingly, when
fetal porcine cells were transplanted into patients
with basal ganglia infarcts, the patients exhibited
significant neurological improvements [3].
2.2

Olfactory ensheathing cells

Human olfactory tissue has the ability to
regenerate and restore itself throughout one’s
whole life [4]. Olfactory neurons show the
characteristic of photoreceptor cells in vitro in
special medium [5]. OECs share characteristic of
SCs and oligodendrocytes and have a strong
ability to secrete neurotrophic factors. These
properties alleviate the lesioned area and

improve the microenvironment to trigger or
restore the damaged neurons through the neuro‐
restorative mechanisms [6, 7]. Olfactory neurons
and OECs are novel and the most potent cells for
restoring the damaged neurological structure and
functions in the central nervous system (CNS).
Transplantation of OECs from aborted fetal
olfactory bulbs were shown to improve
neurological function in patients with chronic
complete spinal cord injury (SCI) [8, 9]. This was
further confirmed by Rabinovich et al., who
found similar results for OEC transplantation in
patients with SCI [10]. A majority of researchers
observed similar positive results after OEC
transplantation in SCI patients across the world
[11–28]. However, only a few studies observed
negative results [28, 29] which probably due to
the damage caused by the procedure itself [30].
Using transplantation of olfactory mucosa
autografts in SCI patients, Lima et al. showed
some functional improvements [31, 32]. There
have also been some negative reports using
Lima’s technique [33, 34]. On the other hand,
Dlouhy et al. reported the formation of a mass
after olfactory mucosal tissue transplantation
[35]. Apart from SCI, other diseases or damage
of the CNS, such as stroke, cerebral palsy (CP),
amyotrophic lateral sclerosis (ALS), and brain
injury, also exhibited neurorestorative effects
after OEC therapy [36–50].
2.3

Mononuclear cells

Unmanipulated MNCs are generally derived
from the bone marrow, cord blood, and the
peripheral blood. Syková et al. transplanted
autologous bone marrow MNCs (BMMNCs)
and described neurological improvements in
patients with subacute and chronic SCI [51].
Autologous undifferentiated peripheral blood
MNCs also showed recovery of the somatosensory
evoked potential responses [52]. Later several
studies demonstrated similar results using
Journal of Neurorestoratology
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autologous BMMNC therapy [53–58]. In one
study, autologous umbilical cord blood trans‐
fusions were used for CP and showed signi‐
ficant improvements in gross motor function
classification system [59]. Intrathecal infusion of
autologous BMMNCs in CP also improved
patients’ motor, sensory, cognitive, and speech
functions [60]. These observations have been
further confirmed by several reports of autolo‐
gous BMMNCs in CP showing similar clinical
functional improvements [61–74]. However,
compared with placebo, Rah et al. reported that
intravenous infusion of peripheral blood MNCs
in a randomized, double‐blind, crossover study
failed to show any significant effect on upper
extremity function in children with CP [75].
Autologous BMMNC therapy was also used
in children with brain injury and was found to
improve neurological function in most patients
[76]. Recently, BMMNC therapies have exhibited
similar positive effects for brain injury patients
[77–79].
Mendonça et al. found that intra‐arterial
autologous BMMNC transplantation was safe in
acute ischemic stroke patients [80]. Autologous
BMMNC therapies for stroke exhibited similar
results in several later studies [81–99]. However,
in a multicenter, randomized trial with blinded
outcome assessment, Prasad et al. found that
autologous BMMNC therapy did not show
beneficial effects in subacute ischemic stroke
patients [100]. Similarly, a recent multicenter,
randomized, blinded assessment, sham‐con‐
trolled trial demonstrated that autologous bone
marrow‐derived ALD‐401 cells given through
the internal carotid artery in patients recovering
from ischemic stroke did not result in any
differences between the groups [101].
A series of reports showed that autologous
BMMNC therapy could improve quality of life
in muscular dystrophy patients [102–105], and
that it showed good benefit in autism [106], ALS
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[107], and brachial plexus injury [108]. Hogen‐
doorn et al. reported that local injection of
autologous BMMNCs in patients with traumatic
brachial plexus injury enhances muscle reinner‐
vation and induce regeneration [109].
2.4

Mesenchymal stromal cells

Before 2005, the plastic‐adherent cells isolated
from bone marrow and other sources were
widely named as either mesenchymal stem cells
or MSCs. However, the International Society for
Cellular Therapy stated that “the recognized
biologic properties of the unfractionated popul‐
ation of cells do not seem to meet generally
accepted criteria for stem cell activity, rendering
the name scientifically inaccurate and potentially
misleading to the lay public” [110]. Thus, the
cells should be named MSCs, and their criteria
should be established [111, 112]. In this article,
we use MSCs to replace mesenchymal stem cells,
except when identified by special stem cell
markers or differentiated into target or effecor
cells. MSCs have been used to treat patients
with varying diseases through intravascular,
subarachnoid, or direct injection into the lesion
area.
Data revealed that autologous MSCs were
safe and well‐tolerated in patients with ALS [113,
114]. This treatment significantly slowed down
the linear decline of the forced vital capacity
[115]. Later, most clinical studies using MSCs
reported neurological stabilization or functional
improvements in ALS [116–124]. On the other
hand, in a few studies, using MSCs did not
interfere with the course of the disease [125].
Intravenous infusion of autologous MSCs
appeared to be a feasible and safe treatment to
improve functional recovery in stroke patients
[126], followed by a series similar results
[127–132]. A randomized, double‐blind, placebo‐
controlled, phase 2 trial of multipotent adult
progenitor cells derived from bone marrow for
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patients with acute ischemic stroke did not show
any difference in neurological recovery between
CT and placebo groups at 90 days [133]. Using
MultiStem from Athersys, Inc. and a protocol
similar that reported by Hess et al. [134], Osanai et
al. conducted another clinical trial [135].
A study using umbilical cord MSC transplantation
reported improvement in sensory perception
and mobility of a patient with SCI [136]. This
finding was corroborated in later studies of MSC
therapy resulting in similar results [137–148].
Interestingly, using the same setup, Chotivichit
et al. reported a negative result [149]. Likewise,
in a phase 3 study, Oh et al. also reported no
improvement in neurological function in the
majority of the patients in their study [150].
Autologous bone marrow MSC transplantation
was applied in patients with paraplegia and was
found to result in improved neurological
function and enhanced quality of life [151–153],
diffused axonal injury [154], neuropathic pain
[155], post‐traumatic syringomyelia [156], and
Alzheimerʹs dementia [157].
In addition, there have been several explorations
of MSCs in clinics that have shown remarkable
neurorestorative effects with improved quality of
life in patients with multiple system atrophy‐
and spinocerebellar ataxia [158, 159], MS [160,
161], brain injury [162, 163], CP [164–168], and
autonomic nervous system dysfunctions [169].
In a randomized, placebo‐controlled, multiple‐
dose study of human placenta‐derived cells
(PDA‐001) in patients with multiple sclerosis (MS),
Lublin et al. found that, although it was safe and
well‐tolerated, its efficacy was uncertain [170].
2.5

Fetal brain and spinal cord cells

Clincial studies have shown that intraspinal
transplantation of fetal spinal cord cells for
patients with ALS is safe [171–174] and capable
of improving their functions [175]. However, it
did not show differences in the mean rates of

progression compared with historical control
groups [176]. Transplantation of neural
cell‐derived fetal brain in a patient with primary
torsion dystonia showed some functional
improvement [177]. Liu et al. transplanted human
fetal‐derived retinal progenitor cells in patients
with retinitis pigmentosa and reported significant
improvement in the visual acuity [178].
2.6

Schwann cells

One study of autologous SC transplantation in
patients with chronic thoracic SCI was
completed. It was observed that, although it was
safe, the procedure did not show any beneficial
effects [179, 180]. On the other hand, transplan‐
tation of SCs could improve some functions in
patients with SCI [181] and even in Parkinson’s
disease [182].
2.7

Combination cell therapies

Cells from immature nervous and hemopoietic
tissues were subarachnoidally transplanted in
patients with subsequent consequences of brain
stroke and improved their neurological function
[36]. They also found similar functional
neurological improvements using this method
in patients with CP and brain injury, including
patients in a comatose state [37–40].
Patients with progressive muscular dystrophy
improved their functions after bone marrow and
umbilical cord blood MSC transplantations [183].
Intravenous transplantation or the intrathecal
injection of human cord blood MNCs with
umbilical cord‐derived MSCs induced a marked
benefit in autism patients [184]. Yazdani et al.
found that autologous SC and bone marrow
MSC cotransplantation was safe in patients with
chronic SCI [185]. In a long‐term follow‐up
study, the patients showed improvement in
some sensation with bladder compliance, but no
further motor function improvement [186].
Chen et al. described the amelioration of
Journal of Neurorestoratology
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neurological functions after multiple cell
transplantation, including OEC, neural progenitor
cells, umbilical cord MSCs, and SCs, in patients
with chronic stroke [46]. Multiple cell therapy,
including umbilical cord MSCs, SCs, neural
progenitor cells, and OECs, was also able to
improve or stabilize the neurological status of
patients with multiple system atrophy [47]. A
combination of OECs and SCs also showed
some functional improvement in patients with
chronic complete SCI [187].
Scaffold implantation after scar resection with
autologous BMMNCs in patients with complete
chronic SCI exhibited some functional improve‐
ments [188–190]. It should be strongly cautioned
that the procedure of total scar resection
deprives the ability of nerves in autorestoring
possibilities. Currently, CT with intensive neuro‐
rehabilitation could partially restore standing
and walking abilities in patients with complete
chronic SCI with improved qualities of daily
life [15].
Bone marrow MSC and BMMNC transplan‐
tation for spastic CP showed neurorestorative
effects [191]. Local transplantation of autologous
type 1 macrophages, autologous tissue‐specific T
helper 1 cell, and autologous muscular progenitor
cells in patients with atrophied muscles exhibited
progressive muscle volume increase with gradual
replacement of hyperechogenic muscle tissues
[192].

3

Developmental process and current state
of stem cell‐derived cell theraphy products

Stem cell‐derived CT products in the nervous
system include hematopoietic stem cells (HSC),
cells differentiated from embryonic stem cells
(ESCs), induced pluripotent stem cells, mesen‐
chymal stem cells, and neural stem cells (NSCs).
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3.1

Hematopoietic stem Cells

Several research teams have started to use blood
HSCs for MS since the last decade of the 20th
century. Fassas et al. reported a distinct clinical
benefit of peripheral blood HSC transplantation
in patients with progressive MS [193] that was
much better than any other treatments [194].
However, multicenter data has suggested
significant mortality risks associated with HSC
therapy [195].
Later, the teams of Burt et al. [196–201], Nash
et al. [202–206], and others described similar
results [207–240]. General autologous HSC
transplantation may not be a curative treatment
for MS, but it could prolong stabilization or
changes in the aggressive course of the disease
[241].
Because most of the studies have been
conducted in small, single‐center, phase 1 and 2
non‐double‐blind trials, it is important for a
prospective, randomized, double‐blind, controlled
multicenter trial to assess the clinical efficacy of
HSC transplantation for the treatment of highly
active MS [242]. Unfortunately, there have been
no such trials reported so far in this field.
HSCs could also improve the function and
quality of life of patients with other nervous
system diseases or damage. Umbilical cord
blood HSC transplantation may restore dystrophy
in muscles and improve the locomotor functions
in patients with Duchenne muscular dystrophy
[243, 244]. A direct injection of autologous bone
marrow HSCs may improve movements and
sensations in patients with chronic SCI and
could effectively treat ALS patients [245, 246].
However, unmodified HSCs did not benefit
patients with sporadic ALS [247]. Purified
autologous leukapheresis derived CD34+ and
CD133+ stem cells improved segmental sensory
functions in patients with chronic SCI during
long‐term evaluation and follow‐up [248]. After
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mobilizing bone marrow CD34+ stem cells by
granulocyte‐colony stimulating factor, it may
offer some benefit to stroke patients as well
[249–253].
3.2 Cell differentiated from embryonic stem
cells
In the first clinical trial from Geron regarding
human ESCs, enrolled patients did not show
any benefits [254]. Transplantation of human
ESC‐derived retinal pigment epithelium in
patients with age‐related macular degeneration
and Stargardt’s macular dystrophy showed
improvements in visual acuity [255]. Transplan‐
tation of an embryonic stem cell‐derived retinal
pigment epithelium patch in 2 patients with
age‐related macular degeneration resulted in a
significant gain in visual acuity [256].
3.3 Cell differentiated from induced pluripotent
stem cells
Autologous induced stem‐cell‐derived retinal
cells for macular degeneration did not show any
improvement in visual acuity [257].
3.4 Cell differentiated from mesenchymal stem
cells
Neural stem cell‐like cells derived from autologous
HSCs have been used in patients with CP and
have shown improvements in motor deficit [258].
Intraspinal delivery of bone marrow stromal
cell‐derived NSCs in patients with ALS resulted
in a temporary stabilization for the first few
months after injection, then gradually
deteriorated [259]. Transplantation of cell‐derived
MSCs in patients with chronic stroke improves
clinical outcome [260, 261]. Patients with severe
traumatic brain injury showed improved
neurological functions in different degrees
after autologous MSC‐derived NSC‐like cell
transplantation [262].

3.5

Cell differentiated from neural stem cells

After USFDA approval [263], Selden et al.
applied HuCNS‐SC transplantation in children
with neuronal ceroid lipofuscinosis [264]. Levi et
al. reported intramedullary transplantation
HuCNS‐SC in patients with SCI [265]. Later, in a
similar single‐blind, randomized proof‐of‐concept
study the following year, cell transplantation
was found below the required clinical efficacy
threshold [266]. Some reports of neural stem and
progenitor cell therapy showed their safety with
or without neurological improvement in
children with CP [267], SCI [268, 269] or stroke
[270, 271].
3.6

Others

Autologous transplantation of CD133+ stem
cells for patients with ALS was found to be safe
[272, 273]. CD133‐positive enriched bone marrow
progenitor CT in children with CP showed
possible short‐term neurological improvements
[274].
3.7

Combination cell therapy

Combined protocol of CT (autoimmune T and
NSCs transdifferentiated from bone marrow
MSCs) have been used in 2 patients with SCI
and resulted in motor and sensory improve‐
ments [275]. In a follow‐up study by the same
team, it was observed that BMMNC in
combination with T cell autologous NSCs
therapy dramatically improves neurological
function in patients with chronic complete SCI
[276]. In addition, the autologous NSC treatment
combined with T cells also showed some
benefits in ALS patients [277]. Cotransplantation
of neural stem and progenitor cells and MSCs
resulted in improvements of some functions in
patients with stroke [278]. Co‐infusion of
autologous adipose tissue‐derived neuronal
differentiated MSCs and bone marrow‐derived
Journal of Neurorestoratology
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HSCs in a patient with post‐traumatic brachial
plexus injury showed sustainable recovery [279,
280]. Motor and objective sensory improvements
have been noted using biological scaffold with
autologous HSCs and platelet‐rich protein in
patients with SCI [281].

4

Reasons of limited effects

Compared with the clinical neurorestorative
effects of OEC transplantation in early 2001, the
overall effects of these CTs are now at the
plateau or in the period of bottleneck without
any breakthrough. So far, CT explorations have
expanded horizontally, showing certain neuro‐
restorative effects on a larger scale, e.g., different
cell types, various implantation cell ways or
methods, different implant sites, and implanting
cell numbers together with different lesions or
disease stages.
The following could be reasons for these
limited effects: (1) unable to know which type of
CTs are more potent candidates, or which
method of transplantation or dosage is more
suitable with the appropriate CT window for
different diseases or damage, as well as whether
repeated CTs have better effects; and (2) CT
products with different quality control and
standards have different effects [282].

5 Summary and future prospective
Varying CTs have been explored for use in CNS
diseases over the past two decades. The majority
of CTs have shown positive results, but most of
them were small, single‐center, phase 1 and 2
non‐double‐blind trials or retrospective clinical
studies in CNS. At present, a few prospective,
multicenter, randomized, double‐blind placebo‐
control clinical trials of CTs have been
conducted but did not show positive results.
These CTs have been shown to restore damaged
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neurological function and/or structure in lower
level evidence‐based medical practice. Thus,
more clinical trials of CTs in the CNS should be
conducted in the future to explore the types of
cells that have affirmative effects with a high
level of evidence‐based medical practice. Also,
greater professional standards of CT products
and quality control are needed in such clinical
trials.
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